Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma

References

• Cunningham B A, Hemperly J J, Murray B A, Prediger E A, Brackenbury R, Edelman G M. Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science 1987; 236: 799–806
   PubMed Web of Science ®Google Scholar
• Lanier L L, Testi R, Bindi J, Phillips J H. Identity of Leu-19 (CD56) leucocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989; 169: 2233–2238
   PubMed Web of Science ®Google Scholar
• Barker H F, Hamilton M S, Ball J, Drew M, Franklin I. Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells. Br J Haematol 1992; 81: 331–335
   PubMed Web of Science ®Google Scholar
• Drach J, Gattringer C, Huber H. Expression of the neural cell adhesion molecule (CD56) by human myeloma cells. Clin Exp Immunol 1991; 83: 418–422
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C, Barille S, Puthier D, Rapp M I, Harousseau J L, Bataille R Amiot M. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading and immortalization. Cancer Res 1995; 55: 3647–3653
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C, Barille S, Jego G, Puthier D, Robillard N, Pineau D, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998; 12: 1977–1982
   PubMed Web of Science ®Google Scholar
• Van Camp B, Durie B GM, Spier C, de Waele M, van Riet I, Vela E, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 1990; 76: 377–386
   PubMed Web of Science ®Google Scholar
• Van Riet I, de Waele M, Remels L, Lacor P, Schots R, van Camp B. Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells. Br J Haematol 1991; 79: 421–427
   PubMed Web of Science ®Google Scholar
• Ely S A, Knowles D M. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 2002; 160: 1293–1299
   PubMed Web of Science ®Google Scholar
• Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 2002; 117: 882–885
   PubMed Web of Science ®Google Scholar
• Sahara N, Takeshita A. Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens. Leuk Lymphoma 2004; 45: 61–65
   PubMed Web of Science ®Google Scholar
• Mateo G, Castellanos M, Rasillo A, Gutierrez N C, Montalban M A, Martin M L, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005; 11: 3661–3663
   PubMed Web of Science ®Google Scholar
• Kaiser U, Auerbach B, Oldenburg M. The neural cell adhesion molecule NCAM in multiple myeloma. Leuk Lymphoma 1996; 20: 389–395
   PubMed Web of Science ®Google Scholar
• Rawstron A C, Barrans S L, Blythe D, Davies F, English A, Pratt G, et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol 1999; 104: 138–143
   PubMed Web of Science ®Google Scholar
• Chang H, Bartlett E S, Paterson B, Chen C I, Yi Q L. The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. Br J Haematol 2005; 129: 539–541
   PubMed Web of Science ®Google Scholar
• Mori A, Tsutsumi Y, Hashino S, Kanamori H, Ibata M, Mashiko S, et al. CD56 expression is the potent prognostic marker of the thalidomide efficacy in the patients with multiple myeloma. Blood 2005; 106: 368b–369b, (abstr 5142)
   PubMed Web of Science ®Google Scholar
• Chang H, Samiee S, Yi Q L. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma 2006; 47: 43–47
   PubMed Web of Science ®Google Scholar
• Leo R, Boeker M, Peest D, Hein R, Bartl R, Gessner J E, et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol 1992; 64: 132–139
   PubMed Web of Science ®Google Scholar
• Matthew P, Ahmann G J, Witzig T E, Roche P C, Kyle R A, Greipp P R. Clinicopathological correlates of CD56 expresion in multiple myeloma: a unique entity?. Br J Haematol 1995; 90: 459–461
   PubMed Web of Science ®Google Scholar
• Greipp P R, San Miguel J, Durie B GM, Crowley J J, Barlogie B, Bladé J, et al. International Staging System for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420
   PubMed Web of Science ®Google Scholar
• Miwa H, Mizutani M, Mahmud N, Yamaguchi M, Takahashi T, Shikami M, et al. Biphasic expression of CD4 in acute myelocytic leukemia (AML) cells: AML of monocyte origin and hematopoietic precursor cell origin. Leukemia 1998; 12: 443–451
   Google Scholar
• Davis K A, Abrams B, Hoffman R A, Bishop J E. Quantitation and valence of antibodies bound to cells. Cytometry 1996; AC 150(Suppl 8)150
   Google Scholar
• Peto R, Pike M C, Armitage P, Breslow N E, Cox D R, Howard S V, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123
   PubMed Web of Science ®Google Scholar
• Kraj M, Pogłód R, Szpila T, Warzocha K. The efficacy and safety of bortezomib in the treatment of plasma cell leukemia. Acta Haematol Polonica 2007; 38(Suppl 1)156–157
   Google Scholar
• Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau J-L, Moreau P, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy. Haematologica 2006; 91: 1234–1240
   PubMed Web of Science ®Google Scholar
• Lin P, Owens R, Tricot G, Wilson C S. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004; 121: 482–488
   PubMed Web of Science ®Google Scholar
• Kraj M, Kopeć-Szlęzak J, Pogłód R, Sokołowska U, Kruk B (2007) Homogenous and non-homogenous CD138 expression on myeloma plasma cells. Proceedings of the 13th International Congress of Immunology, Rio de JaneiroBrazil, August, 21 – 252007, J Kalil, E Cunha-Neto, L V Rizzo. Medimond, BolognaItaly, 187–192, Also at: Haematologica 2007; 92 (Suppl 1): 363 (abstr 975)
   Google Scholar
• Hubschmann M V, Skladchikova G, Bock E, Berezin V. Neural cell adhesion molecule function is regulated by metalloproteinase – mediated ectodomain release. J Neurosci Res 2005; 80: 826–837
   PubMed Web of Science ®Google Scholar
• Jarahian M, Watzl C, Issa Y, Altevogt P, Momburg F. Blockade of natural killer cell-mediated lysis by NCAM expressed on tumor cells. Int J Cancer 2007; 120: 2625–2634
   PubMed Web of Science ®Google Scholar
• Tassone P, Gozzini A, Goldmacher V, Shammas M A, Whiteman K R, Carrasco D R, et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 2004; 64: 4629–4636
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A A, Jagannath S, Schlossman R L, Fram R J, Falzone R M, Ruberti M F, et al. Phase I study of BB-10901 (huN901-DM1) in patient with relapsed and relapsed/refractory CD56 – positive multiple myeloma. Blood 2006; 108(Suppl), abstr 3574
   Google Scholar
• Nadav L, Katz B Z, Baron S, Cohen N, Naparstek E, Geiger B. The generation and regulation of functional diversity of malignant plasma cells. Cancer Res 2006; 66: 8608–8616
   PubMed Web of Science ®Google Scholar
• Edvardsen K, Chen W, Rucklidge G, Walsh F S, Obrink B, Bock E. Transmembrane neural cell-adhesion molecule (NCAM), but not glycosyl-phosphatidylinositol-anchored NCAM, down-regulates secretion of matrix metalloproteinases. Proc Natl Acad Sci USA 1993; 90: 11463–11467
   PubMed Web of Science ®Google Scholar
• Sahara N, Takeshita A, Ono T, Sugimoto Y, Kobayashi M, Shigeno K, et al. Role for interleukin-6 and insulin-like growth factor-I via PI3-K/Akt pathway in the proliferation of CD56− and CD56+ multiple myeloma cells. Exp Hematol 2006; 34: 736–744
   PubMed Web of Science ®Google Scholar
• Hundemer M, Klein U, Hose D, Raab M S, Cremer F W, Jauch A, et al. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transpl, in press
   PubMed Web of Science ®Google Scholar
• Dahl I M, Rasmussen T, Kauric G, Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol 2002; 116: 273–277
   PubMed Web of Science ®Google Scholar
• Schwartz T H, Rhiew R, Isaacson S R, Orazi A, Bruce J N. Association between intracranial plasmacytoma and multiple myeloma: clinicopathological outcome study. Neurosurgery 2001; 49: 1039–1044
   PubMed Web of Science ®Google Scholar
• Kouno T, Watanabe T, Umeda T, Beppu Y, Kojima R, Sungwon K, et al. CD56 – positive small round cell tumor: osseous plasmacytoma manifested in osteolytic tumors of the iliac bone and femora. Jpn J Clin Oncol 2005; 35: 90–93
   PubMed Web of Science ®Google Scholar
• Grogan T M, Spier C M, Salmon S E, Matzner M, Rybski J, Weinstein R S, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490–495
   PubMed Web of Science ®Google Scholar